The FY23 Defense Appropriations Act provides funding for the Pancreatic Cancer Research Program to support research of exceptional scientific merit and innovation with high impact that focuses on pancreatic cancer.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
